Early biochemical textbooks reference certain
carboxypeptidase inhibitors, of which one of the most
potent amino acids included was D-Phenylalanine. Years
later, studies of D-Phenylalanine demonstrated three
important roles for the amino acid; analgesic, antiinflammatory and anti-craving. Further studies revealed
that certain enzymes were responsible for the breakdown
of brain opioid peptides. Brain studies indicated that DPhenylalanine inhibited the enzyme,
enkephalinase. Injections of D-Phenylalanine resulted in
inhibition of enkephalinase and higher levels of the brain
opioid enkephalin. While D-Phenylalanine alone is
considered a drug, DL-Phenylalanine, which is in Crave
Control, is considered a neutraceutical, and is as effective
as D-Phenylalanine, only at a slightly higher dose.
Further studies have demonstrated that low dopamine D2
receptors and/or low amounts of dopamine released at the
synapse in the brain, will lead to craving behavior. It is
further understood that if D2 receptors are continually
stimulated, a positive feedback will induce the
development of additional D2 receptors. Therefore, if D2
receptors are compromised in the human, then stimulating
D2 receptors with dopamine will reduce craving behavior.
Anti-craving behavior can be induced if there is a means
of continually releasing dopamine at the reward site of the
brain in the mesolimbic system, and even in a genetically
compromised individual, existing craving behavior can be
improved.
In addition to DL-Phenylalanine, Crave Control contains
the necessary ingredients to properly utilize DLPhenylalanine and increase dopamine production.
Ingredients such as L-Tyrosine, L-Glutamine, 5-HTP,
Rhodiola Rosea and P5P help to ensure that healthy levels
of dopamine are encouraged to address “Reward
Deficiency Syndrome” which features multiple
expressions including overeating and carbohydrate
binging. In conclusion, Crave Control causes the synthesis
of the brain reward neurotransmitters such as serotonin
and catecholamines. And through its effect on natural
opioids, will by inhibiting GABA, cause a significant
release of dopamine at the nucleus accumbens. This
release of increased amounts of dopamine creates a
proliferation of D2 receptors, thereby reducing cravings
for carbohydrates. This same improvement in the craving
process can also be approached in other behaviors where
craving is a major concern
